Why chronic microdosing might [be risky to the] heart
There have been several FDA-approved medications with 5HT2B receptor activation withdrawn from the US market due to the risk of VHD with heart valve thickening and murmurs: Fen-Phen (fenfluramine/phentermine) and Redux (dexfenfluramine) in 1997 and Permax (pergolide) in 2007. Roughly 25% of patients taking these medications daily developed new onset VHD according to incidence statistics…
Recent Comments